Pricing

Biogen Inc (BIIB)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Christopher A. Viehbacher
Employees:
8720
225 BINNEY STREET, CAMBRIDGE, MA, 02142
7814642000
    Formally known as:
  • Biogen IDEC Inc.
  • IDEC Pharmaceuticals Corp
Stock Split History
DateRatio
2001-01-18 3:1
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis. It also offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, and pemphigus vulgaris.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available